GlassScriptPhysician profile
Jorge A Rivero
NPI 1013097260
$3,525.76
in general payments reported to CMS, 2019-2025
29 companies · $703 in 2025
The $703 reported for 2025 was more than what 86% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $279 · 2021: $463 · 2022: $230 · 2023: $613 · 2024: $346 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,662.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $632.27 | 2019-2025 | Evenity, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $614.04 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $585.32 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $230.46 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $161.90 | 2023-2025 | Rexulti, Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $158.24 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.30 | 2019-2024 | Xifaxan |
| Lundbeck LLC | $111.17 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $101.79 | 2020-2025 | Capvaxive, Vaxneuvance, Pneumovax 23 |
| Astellas Pharma US INC | $90.90 | 2019-2021 | |
| Abbvie INC. | $77.90 | 2022-2023 | Vraylar |
| Amarin Pharma, INC. | $74.19 | 2020 | |
| Pfizer INC. | $58.28 | 2019-2025 | |
| Sanofi Pasteur INC. | $56.95 | 2019-2023 | |
| Radius Health, INC. | $52.72 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $49.08 | 2022-2023 | Crysvita |
| Exact Sciences Corporation | $44.06 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $43.66 | 2024-2025 | Kisunla, Amyvid |
| Inari Medical, INC. | $41.89 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Glaxosmithkline, LLC. | $40.49 | 2023-2025 | Shingrix, Arexvy |
| Novo Nordisk INC | $40.35 | 2021-2022 | |
| Biogen, INC. | $32.54 | 2021 | |
| Allergan, INC. | $18.83 | 2020 | |
| Stryker Corporation | $17.62 | 2025 | Ivas |
| Sun Pharmaceutical Industries INC. | $16.90 | 2021 | |
| Philips North America LLC | $16.40 | 2022 | |
| Boston Scientific Corporation | $13.01 | 2022 | |
| Seqirus USA INC | $13.00 | 2019 | |
| Endogastric Solutions, INC | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Rivero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.